June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Loss of interleukin-6 mitigates visual deficits caused by elevated IOP
Author Affiliations & Notes
  • Franklin D Echevarria
    Neuroscience, Vanderbilt University, Nashville, TN
  • Rebecca M Sappington
    Neuroscience, Vanderbilt University, Nashville, TN
  • Footnotes
    Commercial Relationships Franklin Echevarria, None; Rebecca Sappington, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2458. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Franklin D Echevarria, Rebecca M Sappington; Loss of interleukin-6 mitigates visual deficits caused by elevated IOP. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2458.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: We demonstrated that IL-6 protects RGCs from apoptosis caused by elevated pressure in vitro. Here, we tested whether loss of IL-6 protects the visual pathway against glaucomatous pathology caused by microbead-induced elevations in IOP. To identify consequences of IL-6 deficiency on glaucomatous pathology, we examined functional visual capacity by measuring changes in VEP waveform, retina to SC transport and visual acuity in 7 month wild-type (WT) and IL-6 knockout (KO) mice.

Methods: IOP was elevated in WT and IL-6 KO mice for 8 weeks using the microbead occlusion model. To determine impact on functional visual capacity, we tested RGC response to light using flash-visual evoked potential (fVEP) and measured differences in the VEP waveform. Additionally, visual acuity was measured using optokinetic tracking (OKT) and retina to superior colliculous (SC) transport capability was determined by injecting flourophore-labeled CTB into the vitreous and measuring transported CTB fluorescent intensity in the SC.

Results: Based on IOP measurements, both WT and KO injected with microbeads experienced ~20% elevations in IOP (p>0.05) compared to animals injected with saline. Interestingly, microbead injected IL-6 KO mice show a preserved P1 amplitude, which is 20% greater (p<0.05) compared to microbead injected WT mice. However, microbead injected WT mice experienced a 23% decrease (p>0.05) in visual acuity compared to saline injected WT mice, an effect not seen in microbead injected KO mice. Additionally, microbead injected IL-6 KO mice show decreased deficits in CTB transport compared to microbead injected WT mice.

Conclusions: In constrast to previous in vitro studies, these data suggest that loss of IL-6 protects visual function from glaucomatous pathology in response to elevated IOP in vivo. Overall, these data suggest that IL-6 could be a therapeutic target for glaucoma associated treatment.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.